- Home
- NRXS vs NXTC Comparison
NRXS vs NXTC Comparison
Compare NRXS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- NXTC
- Stock Information
- Founded
- NRXS 2011
- NXTC 2015
- Country
- NRXS United States
- NXTC United States
- Employees
- NRXS N/A
- NXTC N/A
- Industry
- NRXS
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- NXTC Health Care
- Exchange
- NRXS Nasdaq
- NXTC Nasdaq
- Market Cap
- NRXS 25.8M
- NXTC 24.6M
- IPO Year
- NRXS 2023
- NXTC 2019
- Fundamental
- Price
- NRXS $2.75
- NXTC $11.59
- Analyst Decision
- NRXS Strong Buy
- NXTC Strong Buy
- Analyst Count
- NRXS 1
- NXTC 2
- Target Price
- NRXS $7.00
- NXTC $25.50
- AVG Volume (30 Days)
- NRXS 1.1M
- NXTC 86.7K
- Earning Date
- NRXS 11-12-2025
- NXTC 11-04-2025
- Dividend Yield
- NRXS N/A
- NXTC N/A
- EPS Growth
- NRXS N/A
- NXTC N/A
- EPS
- NRXS N/A
- NXTC N/A
- Revenue
- NRXS $3,217,531.00
- NXTC N/A
- Revenue This Year
- NRXS $62.14
- NXTC N/A
- Revenue Next Year
- NRXS $131.87
- NXTC N/A
- P/E Ratio
- NRXS N/A
- NXTC N/A
- Revenue Growth
- NRXS 41.93
- NXTC N/A
- 52 Week Low
- NRXS $1.33
- NXTC $2.69
- 52 Week High
- NRXS $6.20
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- NRXS 39.71
- NXTC 64.39
- Support Level
- NRXS $2.94
- NXTC $8.51
- Resistance Level
- NRXS $3.96
- NXTC $13.15
- Average True Range (ATR)
- NRXS 0.34
- NXTC 1.65
- MACD
- NRXS -0.11
- NXTC 0.22
- Stochastic Oscillator
- NRXS 3.10
- NXTC 75.77
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.